title: Clinical efficacy of autogenous cancellous bone and fibroblast growth factor 2 combined with frozen allografts in femoral nonunion fractures.
abstract: OBJECTIVE
  To evaluate the efficacy of cortical allograft and fibroblast growth factor 2 (FGF-2)-impregnated autogenous cancellous bone in nonunion fracture repair in dogs.
  
  
  METHODS
  From January 2000 to August 2010, seven dogs underwent cortical allograft and FGF-2-impregnated autogenous cancellous bone implantation for treatment of a femoral nonunion following fracture. Radiographic images were used to assess healing.
  
  
  RESULTS
  The average length of the implanted cortical allograft was 29.1 ± 4.4 mm. A significant improvement in the postoperative percentage of femoral shortening was observed with the experimental treatment, from 85.2 ± 8.2% to 95.0 ± 4.8%. Using radiographic scoring, we analysed the process of bone remodelling. At three months post-surgery, the proximal and distal fracture lines had begun to disappear, and a complete absence was observed after six months. Bacterial infection was detected in two of the seven cases.
  
  
  CONCLUSIONS
  The findings of our study suggest that the combination of cortical allografts with FGF-2 impregnated cancellous autograft may be useful in cases of diaphyseal fracture non-union. The disappearance of the fracture line in dogs with nonunion was recognized at the same phase as the report in which healing process of allograft was evaluated in the experimental ostectomy model using the normal dog.
authors.affiliation: Division of Veterinary Surgery, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan. hiroyuki-akagi@hotmail.co.jp
authors.forename: H
authors.initials: H
authors.lastname: Akagi
authors.forename: H
authors.initials: H
authors.lastname: Ochi
authors.forename: N
authors.initials: N
authors.lastname: Kannno
authors.forename: M
authors.initials: M
authors.lastname: Iwata
authors.forename: T
authors.initials: T
authors.lastname: Ichinohe
authors.forename: Y
authors.initials: Y
authors.lastname: Harada
authors.forename: Y
authors.initials: Y
authors.lastname: Nezu
authors.forename: T
authors.initials: T
authors.lastname: Yogo
authors.forename: M
authors.initials: M
authors.lastname: Tagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Hara
mesh_terms: D000818:Animals; D016025:Bone Transplantation / Q000379:methods / Q000662:veterinary*; D002097:C-Reactive Protein / Q000032:analysis; D015925:Cryopreservation / Q000662:veterinary; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D005260:Female; D005264:Femoral Fractures / Q000628:therapy / Q000662:veterinary*; D005269:Femur / Q000000981:diagnostic imaging / Q000473:pathology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology / Q000627:therapeutic use*; D005599:Fractures, Ununited / Q000628:therapy / Q000662:veterinary*; D008297:Male; D011859:Radiography; D014182:Transplantation, Autologous / Q000662:veterinary; D014184:Transplantation, Homologous / Q000662:veterinary
chemical_list: D016222:Fibroblast Growth Factor 2; D002097:C-Reactive Protein